Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 10

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
):

SCHEDULE OF ANTI-DILUTIVE SECURITIES  

    Weighted average 

    Three months ended  
    Nine months ended 

    September 30  
    September 30 

    2025  
    2024  
    2025  
    2024 
  
    Outstanding stock options 
     104,568  
     88,852  
     103,297  
     69,827 
  
    Pre-funded warrants 
     136,282  
     -  
     45,594  
     - 
  
    Warrants 
     1,360,786  
     144,578  
     659,481  
     110,385 

Research
and development expenses

Research
and development expenses include costs directly attributable to the conduct of research and development programs, including the cost
of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research
and development activities, including clinical trials and professional services. All costs associated with research and development are
expensed as incurred.

The
Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract
manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods
over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts
expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider,
the payments will be recorded as a prepaid expense, which will be amortized or expensed as the contracted services are performed.

Fair
Value Measurement

ASC
820, Fair Value Measurements, (“ASC 820”) provides guidance on the development and disclosure of fair value measurements.
Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. As such, fair
value is a market-based measurement that should be determined based on assumptions that